Monday Sep 19, 2022

New multi-cancer early detection test

Early detection of cancer can dramatically increase the efficacy of curative treatment. Unfortunately, early screening tests exist for only a small number of cancers, meaning most are not diagnosed until symptoms arise in the later stages of the disease.

 

Better cancer screening is, therefore, a major focus area for clinical performance improvement. Marilyn Sherrill talks with Dr. Joe Cummings about a new genomic test that can theoretically screen for more than 50 different types of cancer using a small blood sample, and what the future may hold for this technology.

 

Guest speaker:
Joe Cummings, PhD 
Technology Program Director 
Vizient 

 

Moderator:
Marilyn Sherrill, RN, MBA
Performance Improvement Program Director
Vizient

 

Show Notes:

[01:28] The Grail Galleri liquid biopsy test.

[02:18] Sampling methodology.

[02:55] The analytic process of the Grail Galleri test, and some developmental history.

[04:01] Testing methodology is based on methylation patterns.

[05:36] Results of the clinical studies to-date, and status of ongoing studies.

[08:13] Early adopters include some larger healthcare systems and, potentially, anyone willing to self-pay.

[09:04] Test costs and preliminary cost/benefit anaylsis.

[11:02] Considerations re: payers’ willingness to cover test costs.

[12:09] Looking forward to trial results and potential FDA approval.

[13:05] With many companies doing R&D in the liquid biospy field, the development of competing and complementary tests is to be expected.

 

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Google Podcasts

Android

Stitcher

RSS Feed

Copyright 2022 All rights reserved.

Version: 20221013